JP2024501894A5 - - Google Patents
Info
- Publication number
- JP2024501894A5 JP2024501894A5 JP2023540678A JP2023540678A JP2024501894A5 JP 2024501894 A5 JP2024501894 A5 JP 2024501894A5 JP 2023540678 A JP2023540678 A JP 2023540678A JP 2023540678 A JP2023540678 A JP 2023540678A JP 2024501894 A5 JP2024501894 A5 JP 2024501894A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026017384A JP2026082984A (ja) | 2021-01-04 | 2026-02-05 | Ｂ７ｈ４ターゲティング抗体－薬物コンジュゲートおよびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163133707P | 2021-01-04 | 2021-01-04 | |
| US63/133,707 | 2021-01-04 | ||
| US202163172968P | 2021-04-09 | 2021-04-09 | |
| US63/172,968 | 2021-04-09 | ||
| PCT/US2022/011119 WO2022147532A1 (en) | 2021-01-04 | 2022-01-04 | B7h4-targeted antibody-drug conjugates and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026017384A Division JP2026082984A (ja) | 2021-01-04 | 2026-02-05 | Ｂ７ｈ４ターゲティング抗体－薬物コンジュゲートおよびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024501894A JP2024501894A (ja) | 2024-01-16 |
| JP2024501894A5 true JP2024501894A5 (enExample) | 2025-01-08 |
Family
ID=80222361
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023540678A Pending JP2024501894A (ja) | 2021-01-04 | 2022-01-04 | Ｂ７ｈ４ターゲティング抗体－薬物コンジュゲートおよびその使用方法 |
| JP2026017384A Pending JP2026082984A (ja) | 2021-01-04 | 2026-02-05 | Ｂ７ｈ４ターゲティング抗体－薬物コンジュゲートおよびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026017384A Pending JP2026082984A (ja) | 2021-01-04 | 2026-02-05 | Ｂ７ｈ４ターゲティング抗体－薬物コンジュゲートおよびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11964024B2 (enExample) |
| EP (1) | EP4271713A1 (enExample) |
| JP (2) | JP2024501894A (enExample) |
| KR (1) | KR20230137339A (enExample) |
| AU (1) | AU2022205057A1 (enExample) |
| BR (1) | BR112023013263A2 (enExample) |
| CA (1) | CA3203721A1 (enExample) |
| CL (1) | CL2023001966A1 (enExample) |
| CO (1) | CO2023010206A2 (enExample) |
| IL (1) | IL304168A (enExample) |
| MX (1) | MX2023008000A (enExample) |
| TW (1) | TW202241954A (enExample) |
| WO (1) | WO2022147532A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7664680B2 (ja) | 2017-03-29 | 2025-04-18 | リガケム バイオサイエンシズ， インク． | ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物 |
| KR20220056176A (ko) | 2019-08-02 | 2022-05-04 | 메르사나 테라퓨틱스, 인코포레이티드 | 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물 |
| BR112022013255A2 (pt) * | 2020-01-09 | 2022-09-06 | Mersana Therapeutics Inc | Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo |
| CN116196435B (zh) | 2020-04-02 | 2025-12-02 | 梅尔莎纳医疗公司 | 包含sting激动剂的抗体药物缀合物 |
| WO2022147532A1 (en) | 2021-01-04 | 2022-07-07 | Mersana Therapeutics, Inc. | B7h4-targeted antibody-drug conjugates and methods of use thereof |
| JP2025517340A (ja) | 2022-05-17 | 2025-06-05 | メルサナ セラピューティクス インコーポレイテッド | 癌の治療のためのｂ７－ｈ４標的化抗体－薬物コンジュゲート |
| KR20250120285A (ko) * | 2022-11-08 | 2025-08-08 | 주식회사 리가켐바이오사이언스 | Sting 작용제 |
| WO2024186626A1 (en) * | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
| AU2024380559A1 (en) | 2023-11-17 | 2026-06-04 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| WO2026011052A1 (en) * | 2024-07-02 | 2026-01-08 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Car-t cell therapy for triple negative breast cancer |
| WO2026151884A1 (en) | 2025-01-09 | 2026-07-16 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
| AU2004204463B2 (en) | 2003-01-10 | 2009-02-12 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Catalytic domains of beta(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use |
| US8759490B2 (en) | 2005-03-24 | 2014-06-24 | Millennium Pharamaceuticals, Inc. | Antibodies that bind OV064 and methods of use therefor |
| EP1868647A4 (en) | 2005-03-24 | 2009-04-01 | Millennium Pharm Inc | OV064 BINDING ANTIBODIES AND METHOD FOR THEIR USE |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US8609816B2 (en) * | 2005-12-08 | 2013-12-17 | Medarex, L.L.C. | Human monoclonal antibodies to O8E |
| US9121853B2 (en) | 2006-03-20 | 2015-09-01 | Mayo Foundation For Medical Education And Research | B7-H4 expression on tumor vasculature |
| EP2586458B1 (en) | 2006-12-27 | 2016-08-24 | The Johns Hopkins University | Compositions and methods for treating inflammation and auto-immune diseases |
| AR069747A1 (es) | 2007-11-30 | 2010-02-17 | Medarex Inc | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion |
| WO2009102820A2 (en) | 2008-02-11 | 2009-08-20 | Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services | Modified sugar substrates and methods of use |
| US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| EP2717916B1 (en) | 2011-06-10 | 2017-03-08 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US9676854B2 (en) | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
| GB201115841D0 (en) | 2011-09-13 | 2011-10-26 | Genovis Ab | Protein and method |
| US9422351B2 (en) | 2011-11-03 | 2016-08-23 | The Trustees Of The University Of Pennsylvania | Isolated B7-H4 specific compositions and methods of use thereof |
| AU2013361275B2 (en) | 2012-12-19 | 2016-11-24 | Amplimmune, Inc. | Anti-human B7-H4 antibodies and their uses |
| MX2015010777A (es) | 2013-03-14 | 2016-04-25 | Genentech Inc | Anticuerpos e inmunoconjugados anti-b7-h4. |
| US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| WO2015054659A1 (en) | 2013-10-11 | 2015-04-16 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| TW201625689A (zh) | 2014-09-12 | 2016-07-16 | 建南德克公司 | 抗－ｂ７－ｈ４抗體及免疫結合物 |
| US10626176B2 (en) | 2014-10-31 | 2020-04-21 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind B7-H4 |
| CN107810273B (zh) * | 2015-04-23 | 2022-09-27 | 西纳福克斯股份有限公司 | 用为或衍生自β-(1,4)-N-乙酰半乳糖胺转移酶的糖基转移酶修饰糖蛋白的方法 |
| EP3414328B1 (en) | 2016-02-08 | 2024-01-10 | Synaffix B.V. | Enzymes for trimming of glycoproteins |
| WO2018021301A1 (ja) | 2016-07-26 | 2018-02-01 | 静岡県 | 抗ｂ７－ｈ４抗体 |
| US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| WO2018195302A1 (en) | 2017-04-19 | 2018-10-25 | Bluefin Biomedicine, Inc. | Anti-vtcn1 antibodies and antibody drug conjugates |
| US10814011B1 (en) | 2017-06-16 | 2020-10-27 | Nantbio, Inc. | Anti-B7-H4 antibodies and methods |
| SG11202000387YA (en) | 2017-08-25 | 2020-03-30 | Five Prime Therapeutics Inc | B7-h4 antibodies and methods of use thereof |
| CN112566934B (zh) | 2018-01-23 | 2024-09-17 | 奈斯科尔公司 | B7-h4抗体及其使用方法 |
| BR112020015736A2 (pt) | 2018-02-11 | 2020-12-08 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Anticorpo anti-b7-h4, fragmento de ligação a antígeno do mesmo e uso farmacêutico do mesmo |
| WO2019165077A1 (en) | 2018-02-21 | 2019-08-29 | Five Prime Therapeutics, Inc. | B7-h4 antibody formulations |
| AU2019226009B2 (en) | 2018-02-21 | 2025-11-20 | Five Prime Therapeutics, Inc. | B7-H4 antibody dosing regimens |
| CN108948204B (zh) | 2018-06-15 | 2023-01-13 | 苏州旭光科星抗体生物科技有限公司 | 抗人b7-h4单克隆抗体、鉴定方法、应用和试剂盒 |
| AU2019361923B2 (en) | 2018-10-15 | 2026-07-09 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| CA3117050A1 (en) | 2018-10-29 | 2020-05-07 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
| AU2020288275A1 (en) | 2019-06-06 | 2022-02-03 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Anti-B7-H4 antibody–drug conjugate and medicinal use thereof |
| BR112022013255A2 (pt) | 2020-01-09 | 2022-09-06 | Mersana Therapeutics Inc | Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo |
| US20230112085A1 (en) | 2020-01-30 | 2023-04-13 | Apeximmune Therapeutics Inc. | Anti-b7-h4 constructs and uses thereof |
| KR20220154757A (ko) | 2020-03-18 | 2022-11-22 | 젠맵 에이/에스 | B7h4에 결합하는 항체 |
| CN116196435B (zh) | 2020-04-02 | 2025-12-02 | 梅尔莎纳医疗公司 | 包含sting激动剂的抗体药物缀合物 |
| JP7726534B2 (ja) | 2020-06-30 | 2025-08-20 | 諾納生物（蘇州）有限公司 | 抗ｂ７ｈ４抗体及びその二重特異性抗体および用途 |
| WO2022147532A1 (en) | 2021-01-04 | 2022-07-07 | Mersana Therapeutics, Inc. | B7h4-targeted antibody-drug conjugates and methods of use thereof |
-
2022
- 2022-01-04 WO PCT/US2022/011119 patent/WO2022147532A1/en not_active Ceased
- 2022-01-04 AU AU2022205057A patent/AU2022205057A1/en active Pending
- 2022-01-04 JP JP2023540678A patent/JP2024501894A/ja active Pending
- 2022-01-04 US US17/568,376 patent/US11964024B2/en active Active
- 2022-01-04 EP EP22703107.7A patent/EP4271713A1/en active Pending
- 2022-01-04 BR BR112023013263A patent/BR112023013263A2/pt unknown
- 2022-01-04 KR KR1020237025839A patent/KR20230137339A/ko active Pending
- 2022-01-04 MX MX2023008000A patent/MX2023008000A/es unknown
- 2022-01-04 CA CA3203721A patent/CA3203721A1/en active Pending
- 2022-01-04 TW TW111100248A patent/TW202241954A/zh unknown
-
2023
- 2023-07-02 IL IL304168A patent/IL304168A/en unknown
- 2023-07-03 CL CL2023001966A patent/CL2023001966A1/es unknown
- 2023-07-31 CO CONC2023/0010206A patent/CO2023010206A2/es unknown
-
2024
- 2024-03-05 US US18/595,834 patent/US20240269306A1/en active Pending
-
2026
- 2026-02-05 JP JP2026017384A patent/JP2026082984A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI851552B (zh) | 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物 | |
| TWI847992B (zh) | 抗體-藥物結合物之有效的製造方法 | |
| KR102084806B1 (ko) | 인테그린 αvβ6에 대한 항체 및 암을 치료하기 위한 그의 용도 | |
| JP2023129543A5 (enExample) | ||
| JP2019031565A5 (enExample) | ||
| AU2021203755B2 (en) | Tumor selective macropinocytosis-dependent rapidly internalizing antibodies | |
| JP2022169589A5 (enExample) | ||
| JP2022547434A (ja) | 標的化デンドリマー複合体 | |
| TWI845724B (zh) | 用於偶聯的多肽複合物及其應用 | |
| WO2022171134A1 (zh) | 包含抗cldn18.2的抗体或其抗原结合片段的抗体药物偶联物及其用途 | |
| CN111295201A (zh) | 抗egfr抗体药物结合物（adc）和其用途 | |
| JP2023544143A5 (enExample) | ||
| JP2023510349A5 (enExample) | ||
| JP2025506248A5 (enExample) | ||
| JP2023536155A5 (enExample) | ||
| JP2025513593A5 (enExample) | ||
| JP7130243B2 (ja) | 二重特異性抗体を用いた抗体薬物複合体プラットホーム | |
| US20260021194A1 (en) | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload | |
| CN105828841A (zh) | 抗-efna4抗体-药物缀合物 | |
| CN119371541B (zh) | 一种靶向ror1的结合分子及其应用 | |
| JP2026512687A (ja) | ヒト化ｌ１ｃａｍ抗体－薬物複合体 | |
| CN112996540A (zh) | 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途 | |
| CN101277716A (zh) | 治疗癌症的抗体 | |
| JP2025532500A (ja) | 抗ｈｅｒ２抗体免疫アゴニスト複合体の医薬組成物及びその用途 | |
| CN119701004A (zh) | 抗her2抗体药物偶联物治疗妇科恶性肿瘤的方法和用途 |